Abstract
Background: Current HIV antiretroviral therapies potently suppress virus replication and prevent patients from progressing to AIDS but are unable to completely eliminate HIV due to the existence of dormant viral reservoirs which threaten to reemerge at anytime. Recently, genome-editing technologies that can recognize specific DNA sequences, including viral DNA, are being touted as promising tools for curing HIV, owing to their specificity, ease of use, and ability to be custom designed.
Conclusion: Here, we introduce several novel strategies aimed at eradicating HIV proviruses with state-of-the-art genomeediting technologies and discuss perspectives of these approaches for curing HIV.
Keywords: CRISPR/Cas9, genome editing, HIV, latency, provirus, TALENs, ZFNs.
Graphical Abstract
Current HIV Research
Title:Perspectives of Genome-Editing Technologies for HIV Therapy
Volume: 14 Issue: 1
Author(s): Hirotaka Ebina, Peter Gee and Yoshio Koyanagi
Affiliation:
Keywords: CRISPR/Cas9, genome editing, HIV, latency, provirus, TALENs, ZFNs.
Abstract: Background: Current HIV antiretroviral therapies potently suppress virus replication and prevent patients from progressing to AIDS but are unable to completely eliminate HIV due to the existence of dormant viral reservoirs which threaten to reemerge at anytime. Recently, genome-editing technologies that can recognize specific DNA sequences, including viral DNA, are being touted as promising tools for curing HIV, owing to their specificity, ease of use, and ability to be custom designed.
Conclusion: Here, we introduce several novel strategies aimed at eradicating HIV proviruses with state-of-the-art genomeediting technologies and discuss perspectives of these approaches for curing HIV.
Export Options
About this article
Cite this article as:
Ebina Hirotaka, Gee Peter and Koyanagi Yoshio, Perspectives of Genome-Editing Technologies for HIV Therapy, Current HIV Research 2016; 14 (1) . https://dx.doi.org/10.2174/1570162X13666150807105718
DOI https://dx.doi.org/10.2174/1570162X13666150807105718 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Surgical Strategies for Fertility Preservation in Women with Cancer
Current Women`s Health Reviews Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry Cancer Regulator MicroRNA: Potential Relevance in Diagnosis, Prognosis and Treatment of Cancer
Current Medicinal Chemistry Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Recent Advances in Designing Substrate-Competitive Protein Kinase Inhibitors
Current Pharmaceutical Design Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design <i>Larrea tridentata</i> and its Biological Activities
Current Topics in Medicinal Chemistry Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued)